Want to see HK:6660 full AI Analyst Report?
6660 Stock Chart & Stats
HK$3.49
-HK$0.02(-0.35%)
At close: 4:00 PM EST
HK$3.49
-HK$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeHK$1.20 - HK$6.01
Previous CloseN/A
Volume905.00K
Average Volume (3M)1.38M
Market Cap
HK$1.77B
Enterprise ValueHK$3.40B
Total Cash (Recent Filing)HK$384.72M
Total Debt (Recent Filing)HK$1.76B
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding507,673,700
10 Day Avg. Volume830,500
30 Day Avg. Volume1,376,953
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.28
Price to Sales (P/S)3.03
P/FCF Ratio-20.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)HK$3.68B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 62%–74% indicate durable product-level economics in vaccine manufacturing. This margin buffer helps absorb R&D and commercial spend, supports unit-level profitability if volumes recover, and underpins long-term margin sustainability versus peers.
Integrated R&D-to-manufacturing ModelOwning end-to-end capabilities (R&D through manufacturing and commercialization) creates strategic control over supply, quality, and time-to-market. This vertical model supports long-term margin capture, manufacturing partnerships, and resilience in procurement-driven vaccine markets.
Positive Operating Cash FlowPositive operating cash flow across 2024–2025 shows core operations generate cash despite investment needs. Persistent operating cash inflow reduces short-term liquidity strain, provides runway for R&D or scale-up, and lowers immediate reliance on external financing if maintained.
Bears Say
Revenue Decline And Deep LossesFalling revenue combined with a sharply negative net margin undermines the firm's ability to leverage its gross margins into profits. Continued top-line contraction would pressure operating leverage, impair reinvestment in pipeline development, and increase risk of shareholder dilution to fund operations.
Persistently Negative Free Cash FlowLarge, recurring negative free cash flow signals the company consumes cash after investments, raising structural funding needs. Over months, sustained FCF deficits can force additional debt or equity raises, constrain strategic investments, and elevate refinancing and dilution risks.
Worsening Leverage And Negative ROERising leverage alongside a -23.8% ROE indicates capital erosion and weakening balance sheet health. Increased debt burden with negative returns reduces financial flexibility, raises interest and refinancing risk, and limits capacity to fund development or absorb shocks without external support.
AIM Vaccine Co., Ltd. Class H News
6660 FAQ
What was AIM Vaccine Co., Ltd. Class H’s price range in the past 12 months?
AIM Vaccine Co., Ltd. Class H lowest stock price was HK$1.20 and its highest was HK$6.01 in the past 12 months.
What is AIM Vaccine Co., Ltd. Class H’s market cap?
AIM Vaccine Co., Ltd. Class H’s market cap is HK$1.77B.
When is AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date?
AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 24 days.
How were AIM Vaccine Co., Ltd. Class H’s earnings last quarter?
AIM Vaccine Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.486 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.486.
Is AIM Vaccine Co., Ltd. Class H overvalued?
According to Wall Street analysts AIM Vaccine Co., Ltd. Class H’s price is currently Overvalued.
Does AIM Vaccine Co., Ltd. Class H pay dividends?
AIM Vaccine Co., Ltd. Class H does not currently pay dividends.
What is AIM Vaccine Co., Ltd. Class H’s EPS estimate?
AIM Vaccine Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM Vaccine Co., Ltd. Class H have?
AIM Vaccine Co., Ltd. Class H has 507,673,700 shares outstanding.
What happened to AIM Vaccine Co., Ltd. Class H’s price movement after its last earnings report?
AIM Vaccine Co., Ltd. Class H reported an EPS of -HK$0.486 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of AIM Vaccine Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6660
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AIM Vaccine Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.35%
Trailing 12-Months
Company Description
AIM Vaccine Co., Ltd. Class H
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Brii Biosciences Limited
―
Pharmaron Beijing Co., Ltd. Class H
―
Clover Biopharmaceuticals Ltd.
―